[Federal Register Volume 87, Number 143 (Wednesday, July 27, 2022)]
[Proposed Rules]
[Page 45076]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-16102]



[[Page 45076]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[Docket No. DEA-623]


Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-
diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-
MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-
methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-
diisopropyltryptamine (DiPT) in Schedule I; Withdrawal of Proposed Rule 
and Notice of Hearing

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Withdrawal of proposed rule and withdrawal of notice of 
hearing.

-----------------------------------------------------------------------

SUMMARY: The Drug Enforcement Administration (DEA) is withdrawing a 
proposed rule that was published in the Federal Register on January 14, 
2022, which proposed to place five tryptamine hallucinogens in schedule 
I of the Controlled Substances Act. Upon further consideration, DEA has 
determined that it is appropriate to submit a new request to the 
Department of Health and Human Services (HHS) for an updated scientific 
and medical evaluation and scheduling recommendation for these 
substances. Accordingly, DEA is withdrawing the proposed rule and 
notice of hearing that was published in the Federal Register on July 6, 
2022, and is canceling the public hearing and terminating the pending 
hearing proceedings. DEA may issue a new proposed rule in the future 
regarding these substances if warranted.

DATES: The proposed rule that was published in the Federal Register on 
January 14, 2022 (87 FR 2376) is withdrawn as of July 27, 2022. The 
notice of hearing on the proposed rule that was published in the 
Federal Register on July 6, 2022 (87 FR 40167) is withdrawn as of July 
27, 2022. The public hearing, originally scheduled to commence on 
August 22, 2022, is cancelled, and all proceedings related thereto are 
terminated.

FOR FURTHER INFORMATION CONTACT: Terrence L. Boos, Ph.D., Chief, Drug 
and Chemical Evaluation Section, Diversion Control Division, Drug 
Enforcement Administration; Mailing Address: 8701 Morrissette Drive, 
Springfield, Virginia 22152; Telephone: (571) 362-3249.

SUPPLEMENTARY INFORMATION: On January 14, 2022, DEA published a Notice 
of Proposed Rulemaking (NPRM) in the Federal Register (87 FR 2376) to 
place five tryptamine hallucinogens--specifically, 4-hydroxy-N,N-
diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-
MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-
methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-
diisopropyltryptamine (DiPT)--in schedule I of the Controlled 
Substances Act (CSA) (21 U.S.C. 801, et seq.). The proposed placement 
of these substances in schedule I was based on the scientific and 
medical evaluations and recommendations that the HHS provided to DEA.
    In response to the NPRM, DEA received numerous comments and four 
requests for a hearing on the proposed rule, as provided in 21 U.S.C. 
811(a). DEA scheduled a hearing on the proposed rule and published a 
notice to that effect in the Federal Register on July 6, 2022 (87 FR 
40167). The public hearing was scheduled to commence on August 22, 
2022.
    Upon further consideration, DEA has determined that it is 
appropriate to submit a new request to HHS for an updated scientific 
and medical evaluation and scheduling recommendation for these 
substances in accordance with 21 U.S.C. 811(b) and 21 CFR 1308.43(d).
    Accordingly, DEA's proposed rule published in the Federal Register 
on January 14, 2022 (87 FR 2376), and the notice of hearing on the 
proposed rule published in the Federal Register on July 6, 2022 (87 FR 
40167), are withdrawn. The public hearing scheduled to commence on 
August 22, 2022 is canceled, and all proceedings related thereto are 
hereby terminated. DEA may issue a new proposed rule in the future 
regarding the five tryptamine hallucinogens if warranted.

Signing Authority

    This document of the Drug Enforcement Administration was signed on 
July 22, 2022, by Administrator Anne Milgram. That document with the 
original signature and date is maintained by DEA. For administrative 
purposes only, and in compliance with requirements of the Office of the 
Federal Register, the undersigned DEA Federal Register Liaison Officer 
has been authorized to sign and submit the document in electronic 
format for publication, as an official document of DEA. This 
administrative process in no way alters the legal effect of this 
document upon publication in the Federal Register.

Scott Brinks,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2022-16102 Filed 7-26-22; 8:45 am]
BILLING CODE 4410-09-P